Neutral
Pictet Asset Management Holding SA raised its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 9.3% during the first quarter, accordin...
Neutral
This article focuses on the "Price to sales forward" metric for Gilead Sciences, Inc. (NASDAQ: GILD). It appears to be a stub or an auto-generated pag...
Bullish
Gilead's Trodelvy has received expanded FDA approval for first-line treatment of unresectable locally advanced or metastatic triple-negative breast ca...
Neutral
Banque Cantonale Vaudoise raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 6.8% during the first quarter, according to its ...
Neutral
Gilead Sciences received European Commission approval for a label expansion of its breast cancer drug, Trodelvy, for previously untreated metastatic t...
Gilead is celebrating one year since the U.S. FDA approved its twice-yearly HIV prevention medication, a result of nearly 20 years of research and the...
Neutral
The Vascular Dementia market is projected to reach approximately USD 2,399 million in 2023 and is expected to grow significantly by 2034, driven by in...
Neutral
Evolve Private Wealth LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the 4th quarter, according to the company in i...
Gilead Sciences announced that the FDA has accepted its supplemental new drug application for Yeztugo (lenacapavir) 300-mg tablets as a potential once...
Citi has reiterated its Buy rating on Gilead Sciences (GILD.US) and maintained its price target of $165. This indicates a continued positive outlook o...
Andrew Dickinson, associated with Gilead Sciences, Inc. (NASDAQ: GILD), has filed a Form 144 to notify of proposed sales of 9,000 common shares. The f...
Bullish
Gilead Sciences announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for Yeztugo (lenacapavir) 300-mg tablet as a pot...
Bullish
Gilead Sciences announced that the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for once-weekly oral Yeztugo (lenacapavir) 300-m...
Morgan Stanley Smith Barney LLC filed a Rule 144 notice for 3,000 common shares of Gilead Sciences, Inc. (GILD) listed as performance shares dated Feb...
Neutral
Victory Capital Management Inc. reduced its stake in Gilead Sciences (NASDAQ:GILD) by 3.9% in the fourth quarter, selling 109,808 shares but still ret...
Neutral
Gilead Sciences is donating over 2,000 vials of its antiviral therapy, remdesivir, to Uganda to aid in its Ebola Bundibugyo virus disease (BVD) outbre...
Neutral
UniSuper Management Pty Ltd reduced its stake in Gilead Sciences, Inc. by 22.1% in the fourth quarter, selling 124,258 shares and now owning 437,734 s...
Bullish
The Swiss National Bank reduced its stake in Gilead Sciences by 5.2% in the fourth quarter, now holding 3.4 million shares worth $417.34 million. Desp...
Bullish
Gilead Sciences' stock (GILD) rose by 3.48% due to positive developments in its pipeline, particularly in HIV treatments. Key drivers include positive...
Bullish
The National AIDS Memorial and the Gilead Foundation have announced a three-year, $3 million commitment to expand HIV/AIDS education, community leader...